Literature DB >> 15997098

Differential cytotoxicity of anticancer agents in pre- and post-immortal lymphoblastoid cell lines.

Kaori Sawada1, Keisuke Noda, Hiroto Nakajima, Naoki Shimbara, Yasuhiro Furuichi, Masanobu Sugimoto.   

Abstract

We studied the cytotoxic effect of various anticancer agents on lymphoblastoid cell lines transformed by Epstein-Barr virus. Post-immortal N0005 (post-N0005) is an immortalized cell line derived from pre-immortal N0005 (pre-N0005) accompanied by increased telomerase activity, short-telomere, abnormal karyotypes, mutation of p53 gene, down regulation of p16/Rb and the ability to grow in soft agar medium. Compared with pre-N0005 cells, post-N0005 cells were significantly (p<0.001 by the Student t test) more resistant to the killing activity of seven DNA-modifying agents: camptothecin, etoposide, bleomycin, fluorouracil, thioguanine, melphalan and actinomycin D. However, both pre-N0005 and post-N0005 cells showed similar levels of cytotoxicity against four DNA-non-modifying agents: colchicine, paclitaxel, vincristine and methotrexate. DNA-modifying and DNA-non-modifying agents are distinguished by their different sensitivities with pre-N0005 and post-N0005. Based on these results, we propose that pre-N0005 and post-N0005 cell lines be used as a new method to assess and screen anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15997098     DOI: 10.1248/bpb.28.1202

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Exploiting clinical trial data drastically narrows the window of possible solutions to the problem of clinical adaptation of a multiscale cancer model.

Authors:  Georgios S Stamatakos; Eleni C Georgiadi; Norbert Graf; Eleni A Kolokotroni; Dimitra D Dionysiou
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

2.  Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.

Authors:  Laszlo Markasz; György Stuber; Emilie Flaberg; Asa Gustafsson Jernberg; Staffan Eksborg; Eva Olah; Henriette Skribek; Laszlo Szekely
Journal:  BMC Cancer       Date:  2006-11-13       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.